SG11201906729RA - Topical cyclosporine-containing formulations and uses thereof - Google Patents
Topical cyclosporine-containing formulations and uses thereofInfo
- Publication number
- SG11201906729RA SG11201906729RA SG11201906729RA SG11201906729RA SG11201906729RA SG 11201906729R A SG11201906729R A SG 11201906729RA SG 11201906729R A SG11201906729R A SG 11201906729RA SG 11201906729R A SG11201906729R A SG 11201906729RA SG 11201906729R A SG11201906729R A SG 11201906729RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formulations
- march
- pct
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
WO 17 / 15 1657 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 8 September 2017 (08.09.2017) WIPO I PCT (10) International Publication Number WO 2017/151657 Al 111111111111110111011111111111010111110111011111111011111111111111111111111111110111111 Clin ica lly Sign ifican t Chang e from Base line ( >_ 1Omm) 15% p=0.128 (51) International Patent Classification: A61K 38/13 (2006.01) A61P 27/02 (2006.01) (21) International Application Number: PCT/US2017/020008 (22) International Filing Date: 28 February 2017 (28.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/301,576 29 February 2016 (29.02.2016) US 62/302,058 1 March 2016 (01.03.2016) US 62/302,730 2 March 2016 (02.03.2016) US 62/311,177 21 March 2016 (21.03.2016) US (71) Applicant: OCULAR TECHNOLOGIES SARL [CH/CH]; Route de la Corniche 3B, 1066 Epalinges (CH). (72) Inventors; and (71) Applicants : WEISS, Sidney L. [US/US]; 6 Dawn Lane, Randolph, New Jersey 07869 (US). MITRA, Ashim K. [US/US]; 15065 Stearns Street, Overland Park, Kansas 66221 (US). MCNALLY, Eugene J. [US/US]; 3037 Bosshard Drive, Fitchburg, Wisconsin 53711 (US). (74) Agent: WOODHOUSE, Scott, M.; Medler Ferro Wood- house & Mills PLLC, 8201 Greensboro Drive, Suite 1060, McLean, VA 22102 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [Continued on next page] (54) Title: TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF (57) : Provided herein are formulations for topical 20% ophthalmic formulations containing 0.087-0.093 wt% of cyclosporine, and methods of making and using such formu- lations. In some aspects and embodiments the formulations 1 7 9 may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing dis- eases or conditions, such as ocular diseases or conditions. 10% - 5% - 0% OTX-101 0.09% ;.:,° OTX101 0.05% /ehicle Figure I WO 2017/151657 Al MIDEDIMOMOIDEIR010131EMOHIMMERVOIMIE DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3))
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301576P | 2016-02-29 | 2016-02-29 | |
| US201662302058P | 2016-03-01 | 2016-03-01 | |
| US201662302730P | 2016-03-02 | 2016-03-02 | |
| US201662311177P | 2016-03-21 | 2016-03-21 | |
| PCT/US2017/020008 WO2017151657A1 (en) | 2016-02-29 | 2017-02-28 | Topical cyclosporine-containing formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906729RA true SG11201906729RA (en) | 2019-08-27 |
Family
ID=59744365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906729RA SG11201906729RA (en) | 2016-02-29 | 2017-02-28 | Topical cyclosporine-containing formulations and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10918694B2 (en) |
| EP (2) | EP4410312A2 (en) |
| JP (2) | JP7072517B2 (en) |
| KR (1) | KR20180117661A (en) |
| CN (1) | CN109843316A (en) |
| AU (2) | AU2017227585C1 (en) |
| BR (1) | BR112018067946A8 (en) |
| CA (1) | CA3015626A1 (en) |
| DK (1) | DK3423076T3 (en) |
| ES (1) | ES2981702T3 (en) |
| FI (1) | FI3423076T3 (en) |
| IL (1) | IL268056A (en) |
| MX (1) | MX2018010395A (en) |
| NZ (1) | NZ755442A (en) |
| PL (1) | PL3423076T3 (en) |
| PT (1) | PT3423076T (en) |
| RU (1) | RU2747455C2 (en) |
| SA (1) | SA519410114B1 (en) |
| SG (1) | SG11201906729RA (en) |
| WO (1) | WO2017151657A1 (en) |
| ZA (1) | ZA201904704B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050298A1 (en) | 2012-08-24 | 2014-02-27 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions |
| US20200237859A1 (en) | 2019-01-25 | 2020-07-30 | Newport Research, Inc. | Aqueous suspensions of cyclosporin |
| US11324800B2 (en) | 2015-01-15 | 2022-05-10 | Wellspring Ophthalmics, Inc. | Aqueous suspensions of cyclosporin |
| US20190231885A1 (en) | 2015-11-10 | 2019-08-01 | Sun Pharma Global Fze | Topical formulations and uses thereof |
| CN109843316A (en) | 2016-02-29 | 2019-06-04 | 太阳制药全球公司 | Topical formulations and application thereof containing cyclosporin |
| CN112957450A (en) * | 2019-12-20 | 2021-06-15 | 艾棣维欣(苏州)生物制药有限公司 | Aqueous solution of insoluble medicine and preparation method thereof |
| JP2024521968A (en) | 2021-06-14 | 2024-06-04 | サン ファーマシューティカル インダストリーズ リミテッド | Cyclosporine formulations for use in patients undergoing cataract surgery |
| JP2024530244A (en) | 2021-08-20 | 2024-08-16 | サン ファーマシューティカル インダストリーズ リミテッド | Stable cyclosporine ophthalmic formulations and manufacturing process thereof |
| WO2024042550A1 (en) * | 2022-08-25 | 2024-02-29 | Sentiss Pharma Private Limited | Ophthalmic combination composition |
| WO2024098043A2 (en) * | 2022-11-04 | 2024-05-10 | Qlaris Bio, Inc. | Topical ocular delivery of cromakalim |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023010A1 (en) * | 1992-05-13 | 1993-11-25 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
| NZ247516A (en) | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
| US5484597A (en) | 1993-07-30 | 1996-01-16 | Chesebrough-Pond's Usa Co. | Clear hydroalcholic cosmetic microemulsions |
| NZ280689A (en) | 1995-12-15 | 1997-08-22 | Bernard Charles Sherma Sherman | Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol |
| MX9701946A (en) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Transporting ophthalmic solution. |
| US7678836B2 (en) | 1999-11-04 | 2010-03-16 | Fxs Ventures, Llc | Method for rendering a contact lens wettable |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| US20030176356A1 (en) | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| JP2005506990A (en) | 2001-10-19 | 2005-03-10 | アイソテクニカ インコーポレーテッド | A novel microemulsion preconcentrate of cyclosporine analogues |
| WO2004069181A2 (en) | 2003-02-03 | 2004-08-19 | Pharmacia Corporation | Composition for the treatment of intraocular pressure |
| JP2004238346A (en) | 2003-02-07 | 2004-08-26 | Shiono Chemical Co Ltd | Stable aqueous solution preparation of tranilast |
| AU2003228126A1 (en) | 2003-05-02 | 2004-11-23 | Arturo Jimenez Bayardo | Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| ES2314354T3 (en) | 2004-11-09 | 2009-03-16 | Novagali Pharma S.A. | EMULSION OF WATER OIL TYPE WITH LOW CONCENTRATION OF CATIONIC AGENT AND POTENTIAL POSITIVE ZETA. |
| US20090209599A1 (en) | 2005-06-09 | 2009-08-20 | Yoko Endo | Eye drop containing roflumilast |
| CN102772358A (en) | 2005-06-16 | 2012-11-14 | 美瑞德生物工程公司 | Pharmaceutical compositions and use thereof |
| US20070015691A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| PL1904056T3 (en) | 2005-07-18 | 2009-09-30 | Minu Llc | Use of a macrolide to restore corneal sensation |
| US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| JPWO2007126110A1 (en) | 2006-04-24 | 2009-09-17 | ナノキャリア株式会社 | Method for producing low molecular weight drug-encapsulating polymer micelle |
| JPWO2007136134A1 (en) | 2006-05-23 | 2009-10-01 | ナノキャリア株式会社 | Method for producing hydrophobic drug-encapsulating polymer micelle |
| WO2008010341A1 (en) | 2006-07-18 | 2008-01-24 | Nanocarrier Co., Ltd. | Physiologically active polypeptide, polymer micelle having protein enclosed therein, and process for production of the polymer micelle |
| US20100310462A1 (en) | 2007-04-18 | 2010-12-09 | Biochromix Ab | Binding of pathological forms of proteins using conjugated polyelectrolytes |
| US8512687B2 (en) | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
| WO2009028674A1 (en) | 2007-08-29 | 2009-03-05 | Wakamoto Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous pharmaceutical composition |
| MX2007011165A (en) | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine. |
| JP5668476B2 (en) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Ophthalmic composition comprising a calcineurin inhibitor or mTOR inhibitor |
| US20090286718A1 (en) * | 2008-01-04 | 2009-11-19 | Sirion Therapeutics, Inc. | Stable Aqueous Cyclosporin Compositions |
| TWI544927B (en) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | Pharmaceutical compositions having low concentration of surfactants for promoting bioavailability of therapeutic agents |
| AU2009260572B2 (en) | 2008-05-28 | 2015-07-23 | Alcon Research, Ltd. | Self-preserved emulsions |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| US20110040113A1 (en) | 2009-06-02 | 2011-02-17 | Nian Wu | Pure PEG-lipid conjugates |
| CN102458370A (en) | 2009-06-09 | 2012-05-16 | 卢克斯生物科技公司 | Topical drug delivery systems for ophthalmic use |
| EP2478906A4 (en) | 2009-09-17 | 2013-02-20 | Senju Pharma Co | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| EP2538965B1 (en) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| WO2011138801A1 (en) | 2010-05-07 | 2011-11-10 | Sun Pharma Advanced Research Company Ltd. | Novel ophthalmic compositions |
| US20130065888A1 (en) | 2011-08-15 | 2013-03-14 | Biserka Cetina-Cizmek | Ophthalmic formulations and processes for their preparation |
| US9278132B2 (en) | 2012-02-13 | 2016-03-08 | Bausch & Lomb Incorporated | Ophthalmic pharmaceutical compositions and methods of making and using same |
| KR101211902B1 (en) * | 2012-04-30 | 2012-12-13 | 주식회사 휴온스 | Non-irritating ophthalmic nano-emulsion composition comprising cyclosporin |
| RU2014149993A (en) | 2012-05-11 | 2016-07-10 | Сипла Лимитед | PHARMACEUTICAL COMPOSITION |
| CA3050298A1 (en) * | 2012-08-24 | 2014-02-27 | Sun Pharma Global Fze | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and polyalkoxylated alcohol for use in the treatment of ocular conditions |
| US10946076B2 (en) | 2013-02-13 | 2021-03-16 | The Research Foundation For The State University Of New York | Glaucoma treatment |
| JP2017519813A (en) | 2014-05-23 | 2017-07-20 | オキュラー テクノロジーズ エスアーエールエル | Topical formulations and uses thereof |
| US20150352176A1 (en) * | 2014-06-06 | 2015-12-10 | Newport Research, Inc. | Oil-free and fat-free aqueous suspensions of cyclosporin |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20180133217A1 (en) | 2015-05-04 | 2018-05-17 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| US20190231885A1 (en) | 2015-11-10 | 2019-08-01 | Sun Pharma Global Fze | Topical formulations and uses thereof |
| EP3373924A4 (en) | 2015-11-12 | 2019-06-19 | Sun Pharma Global FZE | Topical formulations and uses thereof |
| CN109843316A (en) | 2016-02-29 | 2019-06-04 | 太阳制药全球公司 | Topical formulations and application thereof containing cyclosporin |
| WO2017152129A2 (en) | 2016-03-03 | 2017-09-08 | Ocular Technologies Sarl | Treatment of glaucoma and/or retinal diseases and formulations useful therefore |
-
2017
- 2017-02-28 CN CN201780026587.5A patent/CN109843316A/en active Pending
- 2017-02-28 WO PCT/US2017/020008 patent/WO2017151657A1/en active Application Filing
- 2017-02-28 JP JP2018545269A patent/JP7072517B2/en active Active
- 2017-02-28 NZ NZ755442A patent/NZ755442A/en active IP Right Revival
- 2017-02-28 KR KR1020187027785A patent/KR20180117661A/en not_active Application Discontinuation
- 2017-02-28 PT PT177606431T patent/PT3423076T/en unknown
- 2017-02-28 DK DK17760643.1T patent/DK3423076T3/en active
- 2017-02-28 AU AU2017227585A patent/AU2017227585C1/en active Active
- 2017-02-28 ES ES17760643T patent/ES2981702T3/en active Active
- 2017-02-28 EP EP24169238.3A patent/EP4410312A2/en active Pending
- 2017-02-28 MX MX2018010395A patent/MX2018010395A/en unknown
- 2017-02-28 BR BR112018067946A patent/BR112018067946A8/en unknown
- 2017-02-28 CA CA3015626A patent/CA3015626A1/en active Pending
- 2017-02-28 US US16/079,928 patent/US10918694B2/en active Active
- 2017-02-28 EP EP17760643.1A patent/EP3423076B1/en active Active
- 2017-02-28 FI FIEP17760643.1T patent/FI3423076T3/en active
- 2017-02-28 SG SG11201906729RA patent/SG11201906729RA/en unknown
- 2017-02-28 PL PL17760643.1T patent/PL3423076T3/en unknown
- 2017-02-28 RU RU2019130403A patent/RU2747455C2/en active
-
2019
- 2019-07-14 IL IL268056A patent/IL268056A/en unknown
- 2019-07-17 ZA ZA2019/04704A patent/ZA201904704B/en unknown
- 2019-09-12 SA SA519410114A patent/SA519410114B1/en unknown
-
2021
- 2021-01-07 US US17/143,863 patent/US20210145924A1/en not_active Abandoned
-
2022
- 2022-05-10 JP JP2022077492A patent/JP7547411B2/en active Active
- 2022-05-11 AU AU2022203135A patent/AU2022203135A1/en active Pending
- 2022-09-26 US US17/935,177 patent/US11951153B2/en active Active
-
2024
- 2024-02-28 US US18/590,539 patent/US20240197818A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906729RA (en) | Topical cyclosporine-containing formulations and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201806630QA (en) | Self-propelled personal transportation device | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900609PA (en) | Method and system for providing buffer solutions | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |